Literature DB >> 21459030

Pulmonary function and pathology in hydroxypropyl-beta-cyclodextin-treated and untreated Npc1⁻/⁻ mice.

Akshay Muralidhar1, Ivan A Borbon, Dyadin M Esharif, Wangjing Ke, Rinu Manacheril, Michael Daines, Robert P Erickson.   

Abstract

Lung dysfunction is an important part of the pathology of the neurodegenerative disorder, Niemann-Pick C1 (NPC1). We have studied the pulmonary disease in the Npc1(NIH/NIH) mouse model. On histology, we find large numbers of alveolar foamy macrophages but no alveolar proteinosis. Lung weight as percent of body weight was markedly increased; using the flexiVent small animal ventilator (SCIREQ, Inc.), we find inspiratory capacity, elastance and hysterisivity to be increased while resistance was not changed. Cholesterol measurements show a doubling of lung cholesterol levels. Collagen is also increased. Treatment of Npc1(-/-) mice with hydroxypropyl-β-cyclodextrin (HPBCD), despite efficacious effects in brain and liver, results in little difference from age-matched controls (using a CNS-expressed transgene to extend the life expectancy of the Npc1(-/-) mice) for these variables.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21459030      PMCID: PMC3107736          DOI: 10.1016/j.ymgme.2011.03.001

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  41 in total

1.  Some important considerations in the use of cyclodextrins.

Authors:  J Blanchard; S Proniuk
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

Review 2.  Pulmonary involvement in Niemann-Pick disease: case report and literature review.

Authors:  O A Minai; E J Sullivan; J K Stoller
Journal:  Respir Med       Date:  2000-12       Impact factor: 3.415

3.  Spatial and temporal distribution of nerves, ganglia, and smooth muscle during the early pseudoglandular stage of fetal mouse lung development.

Authors:  J Tollet; A W Everett; M P Sparrow
Journal:  Dev Dyn       Date:  2001-05       Impact factor: 3.780

4.  Parenteral hydroxypropyl cyclodextrins: intravenous and intracerebral administration of lipophiles.

Authors:  J Pitha; A Gerloczy; A Olivi
Journal:  J Pharm Sci       Date:  1994-06       Impact factor: 3.534

5.  Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid.

Authors:  Benny Liu; Charina M Ramirez; Anna M Miller; Joyce J Repa; Stephen D Turley; John M Dietschy
Journal:  J Lipid Res       Date:  2009-11-18       Impact factor: 5.922

6.  Safety of oral cyclodextrins: effects of hydroxypropyl cyclodextrins, cyclodextrin sulfates and cationic cyclodextrins on steroid balance in rats.

Authors:  A Gerloczy; T Hoshino; J Pitha
Journal:  J Pharm Sci       Date:  1994-02       Impact factor: 3.534

7.  Astrocyte-only Npc1 reduces neuronal cholesterol and triples life span of Npc1-/- mice.

Authors:  Min Zhang; Diana Strnatka; Carolyn Donohue; Janice L Hallows; Inez Vincent; Robert P Erickson
Journal:  J Neurosci Res       Date:  2008-10       Impact factor: 4.164

8.  Amelioration of enteric neuropathology in a mouse model of Niemann-Pick C by Npc1 expression in enteric glia.

Authors:  Raj Kapur; Carolyn Donohue; David Jelinek; Robert P Erickson
Journal:  J Neurosci Res       Date:  2009-10       Impact factor: 4.164

9.  Effect of cyclodextrin on plasma lipids and cholesterol metabolism in the rat.

Authors:  M L Favier; C Rémésy; C Moundras; C Demigné
Journal:  Metabolism       Date:  1995-02       Impact factor: 8.694

10.  Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.

Authors:  Cristin D Davidson; Nafeeza F Ali; Matthew C Micsenyi; Gloria Stephney; Sophie Renault; Kostantin Dobrenis; Daniel S Ory; Marie T Vanier; Steven U Walkley
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

View more
  19 in total

1.  Therapeutic potential of cyclodextrins in the treatment of Niemann-Pick type C disease.

Authors:  Benny Liu
Journal:  Clin Lipidol       Date:  2012-06

2.  Systemic administration of 2-hydroxypropyl-β-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function.

Authors:  Adam M Lopez; Sandi J Terpack; Kenneth S Posey; Benny Liu; Charina M Ramirez; Stephen D Turley
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-10       Impact factor: 2.557

3.  A novel mouse model of Niemann-Pick type C disease carrying a D1005G-Npc1 mutation comparable to commonly observed human mutations.

Authors:  Robert A Maue; Robert W Burgess; Bing Wang; Christine M Wooley; Kevin L Seburn; Marie T Vanier; Maximillian A Rogers; Catherine C Chang; Ta-Yuan Chang; Brent T Harris; David J Graber; Carlos A A Penatti; Donna M Porter; Benjamin S Szwergold; Leslie P Henderson; John W Totenhagen; Theodore P Trouard; Ivan A Borbon; Robert P Erickson
Journal:  Hum Mol Genet       Date:  2011-11-02       Impact factor: 6.150

4.  Ontogenic changes in lung cholesterol metabolism, lipid content, and histology in mice with Niemann-Pick type C disease.

Authors:  Charina M Ramirez; Adam M Lopez; Lam Q Le; Kenneth S Posey; Arthur G Weinberg; Stephen D Turley
Journal:  Biochim Biophys Acta       Date:  2013-09-26

Review 5.  Polysaccharide-Based Controlled Release Systems for Therapeutics Delivery and Tissue Engineering: From Bench to Bedside.

Authors:  Tianxin Miao; Junqing Wang; Yun Zeng; Gang Liu; Xiaoyuan Chen
Journal:  Adv Sci (Weinh)       Date:  2018-01-08       Impact factor: 16.806

6.  Synthesis of the Anionic Hydroxypropyl-β-cyclodextrin:Poly(decamethylenephosphate) Polyrotaxane and Evaluation of its Cholesterol Efflux Potential in Niemann-Pick C1 Cells.

Authors:  Kerstin Egele; Shayak Samaddar; Nina Schneider; David Thompson; Gerhard Wenz
Journal:  J Mater Chem B       Date:  2018-12-07       Impact factor: 6.331

7.  Impact of the loss of caveolin-1 on lung mass and cholesterol metabolism in mice with and without the lysosomal cholesterol transporter, Niemann-Pick type C1.

Authors:  Dorothy I Mundy; Adam M Lopez; Kenneth S Posey; Jen-Chieh Chuang; Charina M Ramirez; Philipp E Scherer; Stephen D Turley
Journal:  Biochim Biophys Acta       Date:  2014-04-18

8.  Altered transition metal homeostasis in Niemann-Pick disease, type C1.

Authors:  Ya Hui Hung; Noel G Faux; David W Killilea; Nicole Yanjanin; Sally Firnkes; Irene Volitakis; George Ganio; Mark Walterfang; Caroline Hastings; Forbes D Porter; Daniel S Ory; Ashley I Bush
Journal:  Metallomics       Date:  2013-12-16       Impact factor: 4.526

9.  Extensive macrophage accumulation in young and old Niemann-Pick C1 model mice involves the alternative, M2, activation pathway and inhibition of macrophage apoptosis.

Authors:  Gail Deutsch; Akshay Muralidhar; Ellen Le; Ivan A Borbon; Robert P Erickson
Journal:  Gene       Date:  2015-12-18       Impact factor: 3.688

10.  A pilot study of direct delivery of hydroxypropyl-beta-cyclodextrin to the lung by the nasal route in a mouse model of Niemann-Pick C1 disease: motor performance is unaltered and lung disease is worsened.

Authors:  Robert P Erickson; Gail Deutsch; Ruturaj Patil
Journal:  J Appl Genet       Date:  2018-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.